ReviewWorld journal of gastroenterology2014
Irritable bowel syndrome: a clinical review.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 4 syntheses or guidelines pooled it, 264 citations in OpenAlex.
- GUT MICROBIOTA ALTERATIONS IN RODENT MODELS OF CHOLESTASIS INDUCED BY BILE DUCT LIGATION: A SYSTEMATIC REVIEW.Arquivos de gastroenterologia · 2026Pooled it
- Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis.European journal of nutrition · 2021Pooled it
- Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies.International journal of biological sciences · 2018Pooled it
- Pooled it
- A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation predominant IBS.Scientific reports · 2025Trial
- Trial
- An Open-Label Trial Study of Quality-of-Life Assessment in Irritable Bowel Syndrome and Their Treatment.Medicina (Kaunas, Lithuania) · 2022Trial
- A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome.The Journal of clinical investigation · 2020Trial
- Trial
- Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial.The British journal of nutrition · 2015Trial
- Exploring the role of chronic overlapping pain conditions on smoking dependence, cessation challenges, and internalizing psychopathology among individuals with irritable bowel syndrome who smoke.Journal of behavioral medicine · 2026Article
- Article
- Paradigm Shift of Microbiota-gut-brain Axis During Aging: Potential Role of Probiotics to Improve Cognitive Decline.Probiotics and antimicrobial proteins · 2026Review
- Prevalence of irritable bowel syndrome and its association with lifestyle factors among medical students in Jordan: a cross-sectional survey.Scientific reports · 2026Article
- Toward Safer Diagnoses: A SEIPS-Based Narrative Review of Diagnostic Errors.Diagnostics (Basel, Switzerland) · 2026Review
- Synergistic Modulation of the Gut-Brain-Immune Axis by a DualJournal of microbiology and biotechnology · 2025Article
- Optimizing Nutritional Balance: Integrating the Mediterranean Diet into Low-FODMAP Nutrition.Microorganisms · 2025Review
- Factor Analysis of the BDI-II and HAMD-21 in Patients With Irritable Bowel Syndrome.Alpha psychiatry · 2025Article
- Moderate Wine Consumption and Gastrointestinal Diseases.Nutrients · 2025Review
- An 8-Week Course of Bifidobacterium longum 35624Probiotics and antimicrobial proteins · 2025Observational
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) remains a clinical challenge in the 21(st) century. It's the most commonly diagnosed gastrointestinal condition and also the most common reason for referral to gastroenterology clinics. Its can affect up to one in five people at some point in their lives, and has a significantly impact of life quality and health care utilization. The prevalence varies according to country and criteria used to define IBS. Various mechanisms and theories have been proposed about its etiology, but the biopsychosocial model is the most currently accepted for IBS. The complex of symptoms would be the result of the interaction between psychological, behavioral, psychosocial and environmental factors. The diagnosis of IBS is not confirmed by a specific test or structural abnormality. It is made using criteria based on clinical symptoms such as Rome criteria, unless the symptoms are thought to be atypical. Today the Rome Criteria III is the current gold-standard for the diagnoses of IBS. Secure positive evidence of IBS by means of specific disease marker is currently not possible and cannot be currently recommended for routine diagnosis. There is still no clinical evidence to recommend the use of biomarkers in blood to diagnose IBS. However, a number of different changes in IBS patients were demonstrated in recent years, some of which can be used in the future as a diagnostic support. IBS has no definitive treatment but could be controlled by non-pharmacologic management eliminating of some exacerbating factors such certain drugs, stressor conditions and changes in dietary habits.The traditional pharmacologic management of IBS has been symptom based and several drugs have been used. However, the cornerstone of its therapy is a solid patient physician relationship. This review will provide a summary of pathophysiology, diagnostic criteria and current and emerging therapies for IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.